13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • South Australia - Bladder

    Every day researchers work towards finding new breakthroughs in cancer. Clinical trials play a pivotal role in bringing that defeat closer.

    Clinical trials test promising new treatments on people to see if they are better than existing cancer treatments. The trial process is long starting many years before an actual treatment can be used.

    By joining a clinical trial you are helping to create new breakthroughs in cancer research. Hundreds of thousands of people all over the world have taken part in clinical trials that have lead to safer and more effective treatments for many cancers.

    It is important to note that not all cancer patients are eligible to take part in clinical trials and there are not clinical trials for all types of cancer.

    You may decide to join a clinical trial because:

    • The treatment you receive will be at least the best available for your illness.
    • Your health may improve because of the treatment you receive.
    • You may receive a treatment you would not otherwise have access to.
    • Your health will be carefully checked by the treatment team running the trial.
    • You will be part of the worldwide effort to improve cancer treatment.

    For more information on clinical trials please click here.

    Clinical trial managers:

    If you would like information regarding any of the below clinical trials, please contact the appropriate Clinical trials manager:

    Ashford Cancer Centre: Helen Daykin, +61 8 8292 2240

    Flinders Medical Centre: Alex Scott-Hoy, +61 8 8204 4830

    The Queen Elizabeth:  Sue Yeend, +61 8 8222 6148

    Lyell McEwin Hospitals: Julie Rowe or Rohit Joshi +61 8 8282 0833

    Royal Adelaide Hospital: Anne Milton, +61 8 7074 2342

    Current clinical trials for bladder cancer

    Status Description Organisation
    Recruiting ARCHES A Multinational, Phase 3, Randomized, Double‐blind, Placebocontrolled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) The Queen Elizabeth Hospital
    Recruiting B9991001 JAVELIN A PHASE 3, MULTICENTER, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY OF AVELUMAB (MSB0010718C) PLUS BEST SUPPORTIVE CARE VERSUS BEST SUPPORTIVE CARE ALONE AS A MAINTENANCE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER WHOSE DISEASE DID NOT PROGRESS AFTER COMPLETION OF FIRST-LINE PLATINUM-CONTAINING CHEMOTHERAPY Ashford Cancer Centre Research
    Recruiting BEP3 - Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelereated versus standard BEP chemotherapy for participants with intermediate and poor-risk metastatic germ cell tumours Flinders Medical Centre
    Recruiting BMS 274 A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial Carcinoma The Lyell McEwin Hospital
    Recruiting JAVELIN Bladder 100 A Phase 3, Multicenter, Multinational, Randomized, Open‐Label, Parallel‐Arm Study Of Avelumab* (Msb0010718c) Plus Best Supportive Care Versus Best Supportive Care Alone As A Maintenance Treatment In Patients With Locally Advanced Or Metastatic Urothelial Cancer Whose Disease Did Not Progress After Completion Of First‐Line Platinum‐Containing Chemotherapy The Queen Elizabeth Hospital
    Recruiting A PHASE 3, MULTICENTER, MULTINATIONAL, RANDOMIZED, OPEN- LABEL, PARALLEL-ARM STUDY OF AVELUMAB* (MSB0010718C) PLUS BEST SUPPORTIVE CARE VERSUS BEST SUPPORTIVE CARE ALONE AS A MAINTENANCE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER WHOSE DISEASE DID NOT PROGRESS AFTER COMPLETION OF FIRST-LINE PLATINUM-CONTAINING CHEMOTHERAPY Flinders Medical Centre
    Recruiting W30070 A phase III, multicenter, randomized, placebo-controlled, partially blinded study of Atezolizumab (antipd-l1 antibody) monotherapy and in combination with platinum-based chemotherapy versus platinum-based chemotherapy alone in patients with untreated locally advanced or metastatic urothelial carcinoma Flinders Medical Centre
    Recruiting WO30070 A PHASE 3, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH GEMCITABINE/CARBOPLATIN VERSUS GEMCITABINE / CARBOPLATIN ALONE IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WHO ARE INELIGIBLE FOR CISPLATIN-BASED THERAPY Ashford Cancer Centre Research

    Today at Cancer Council SA

  • Do you have a cancer question?

    Do you have a cancer question?

    Cancer causes questions. Call us for the answers.

  • Donate in lieu of flowers

    Donate in lieu of flowers

    Remembering loved ones by ensuring no one goes through cancer alone.

  • Fundraising events

    Fundraising events

    We have a wide range of exciting events that give you the opportunity to support our vision of a cancer free future in a fun, easy yet symbolic way.

  • Healthy Living after Cancer

    Healthy Living after Cancer

    Getting back to a healthy lifestyle after cancer is one of the most important things you can do for your health. Find out about our Healthy Living after Cancer program.

  • Heard something about cancer and not sure if it's true?

    Heard something about cancer and not sure if it's true?

    Get all the evidence based answers to your cancer questions here.

  • Join the conversation

    Join the conversation

    Follow us on Facebook to stay up to date with the latest community events and news.

  • More than a gift, it's hope for the future

    More than a gift, it's hope for the future

    Including a bequest to Cancer Council SA in your will is not an alternative to looking after your loved ones, it’s part of it. Find out more.

  • Quitline

    Quitline

    Quitline is a government-funded service operated by Cancer Council SA, with the sole goal of providing the support, strategies and information to empower individuals to quit smoking.